Skip to main content

Table 1 Inquiries and approvals for Ranibizumab according to the type of retinal disease, age and gender (source: authors’ analysis of data from Clalit Mushlams’ cohort of members funding applications, March 1, 2012 to December 31, 2015]

From: Cost containment by peer prior authorization program for second line treatment in patients with retinal disease

  AMD Other CNV RVO DME Other Complex Dx Total
n = 3445 n = 16 n = 467 n = 1365 n = 25 n = 324 n = 5642
Age - years, mean ± SD 79.7 ± 9.02 71.6 ± 11.02 61.1 ± 15.61 66.7 ± 9.12 71.1 ± 12.29 70.0 ± 7.73 75.3 ± 11.13
Gender-female, n(%) 1919 (56%) 8 (50%) 234 (50%) 560 (41%) 12 (48%) 134 (41%) 2867 (51%)
Total Inquiries, n 11,107 24 1054 3053 31 1509 16,778
Approved inquiries, n(%) 8700 (78%) 19 (79%) 900 (85%) 2575 (84%) 0 (0%) 1084 (72%) 13,278 (79%)
  1. SD standard deviation, n number of eyes, Age Age at examination, AMD neovascular age related macular degeneration, CNV choroidal neovascularization, RVO retinal vein occlusion, DME diabetic macular edema, Dx diagnosis
Back to article page

Israel Journal of Health Policy Research

ISSN: 2045-4015